A meta-analysis of highly active anti-retroviral therapy for treatment of plasmablastic lymphoma.

Plasmablastic lymphoma is a recently described B-cell derived lymphoma. The prognosis of plasmablastic lymphoma patients is usually poor. We performed a systematic review of the literature on the use of highly active anti-retroviral therapy (HAART) and the prognosis of plasmablastic lymphoma.
A comprehensive search of relevant databases, including Medline, Embase, the Cochrane Controlled Trials Register, the Cochrane Library, and the Science Citation Index yielded ten randomized controlled trials. Trials were divided into two groups according to therapy. The rates of plasmablastic lymphoma were analyzed using a fixed-effects model. Sensitivity analyses (on publication type, statistical model) were performed to further detect and evaluate clinically significant heterogeneity. Tests of survival for plasmablastic lymphoma were also performed by using Kaplan-Meier method.
Meta-analysis result showed that the prognosis of plasmablastic lymphoma patients was statistically different in the patients receiving HAART in addition to chemotherapy and/or radiotherapy than in the patients receiving the chemotherapy and/or radiotherapy alone (pooled relative risk=3.04; P=.03). Survival analyses also displayed a statistically significant difference (chi-square=6.22, P=.013).
HAART in addition to chemotherapy and/or radiotherapy is effective in improving the prognosis of plasmablastic lymphoma. However, the small sample sizes increase the likelihood of bias in the studies in this meta-analysis, and therefore, the results should be taken cautiously.
AuthorsBing Guan, Xinhua Zhang, Henhui Ma, Hangbo Zhou, Xiaojin Zhou
JournalHematology/oncology and stem cell therapy (Hematol Oncol Stem Cell Ther) Vol. 3 Issue 1 Pg. 7-12 ( 2010) ISSN: 1658-3876 [Print] Saudi Arabia
PMID20231808 (Publication Type: Journal Article, Meta-Analysis)
  • Antiretroviral Therapy, Highly Active
  • Humans
  • Lymphoma, Large-Cell, Immunoblastic (drug therapy, mortality, radiotherapy)
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Sample Size
  • Survival Rate
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: